Richard S. Finn

Richard S. Finn, MD is Professor of Medicine at UCLA's David Geffen School of Medicine and one of the leading clinical investigators reshaping the first-line treatment of hepatocellular carcinoma. He was the global principal investigator for the IMbrave150 trial—the phase III study comparing atezolizumab plus bevacizumab versus sorafenib in previously untreated advanced HCC—which demonstrated significant improvements in both overall survival (HR 0.58) and progression-free survival, leading to the FDA approval of the combination in 2020 and displacing sorafenib as the primary standard of care. Dr. Finn was also a steering committee leader for the HIMALAYA trial, which established the STRIDE regimen (single priming dose of tremelimumab plus durvalumab) as another first-line option in HCC. His research interests span the biology of antiangiogenic and immune synergy in HCC, mechanisms of intrinsic and acquired resistance to immunotherapy in the liver microenvironment, and next-generation combination strategies. He also has major expertise in breast cancer and has led pivotal CDK4/6 inhibitor trials, reflecting his broad signal-transduction oncology focus.